结肠癌穿孔的外科处理：危险因素分层与 预后影响

Surgical Management of Colon Cancer Perforation: Risk Factor Stratification and Prognostic Implications

摘要: 结肠癌穿孔是一种罕见但致命的急腹症，其发生率虽低，却显著恶化患者的围手术期结局和长期生存。本文系统综述了结肠癌穿孔的病理生理机制、临床分型、急诊外科处理策略、关键危险因素及其对预后的独立影响，并探讨了当前研究的前沿进展。穿孔主要源于肿瘤直接浸润、梗阻继发缺血或医源性/治疗相关损伤。临床实践中，区分“封闭式穿孔”与“游离穿孔”对预后评估至关重要。外科处理的核心在于个体化决策，Hartmann手术仍是控制严重腹腔感染的金标准，而一期吻合术则适用于经过严格筛选的低风险患者。多项高质量研究已证实，穿孔本身是影响结直肠癌患者总生存期的独立危险因素，而非仅仅是晚期疾病的伴随现象。预后不良的主要原因包括肿瘤细胞腹腔播散导致的高复发率以及患者因急诊手术打击而难以完成规范的辅助化疗。当前研究前沿聚焦于微生物组学、循环肿瘤DNA (ctDNA)等液体活检技术以及人工智能(AI)在精准风险分层和个体化治疗中的应用。未来，通过多学科协作和技术创新，有望改善这一危重患者群体的生存结局。

Abstract: Colon cancer perforation is a rare but fatal acute abdomen. Although its incidence is low, it significantly worsens perioperative outcomes and long-term survival of patients. This article systematically reviews the pathophysiological mechanism, clinical classification, emergency surgical treatment strategy, key risk factors and independent impact on prognosis of colon cancer perforation, and discusses the current research frontier progress. Perforation mainly results from direct tumor invasion, ischemia secondary to obstruction, or iatrogenic/treatment-related injury. In clinical practice, it is very important to distinguish between “closed perforation” and “free perforation” for prognosis evaluation. The core of surgical management lies in individualized decision-making. Hartmann procedure is still the gold standard for the control of severe intra-abdominal infection, while one-stage anastomosis is suitable for low-risk patients after strict screening. A number of high-quality studies have confirmed that perforation itself is an independent risk factor for overall survival in patients with colorectal cancer, rather than just a concomitant phenomenon of advanced disease. The main reasons for poor prognosis include the high recurrence rate caused by intraperitoneal dissemination of tumor cells and the difficulty for patients to complete standard adjuvant chemotherapy due to emergency surgery. Current research frontiers focus on the application of microbiome, liquid biopsy technology such as circulating tumor DNA (ctDNA), and artificial intelligence (AI) in accurate risk stratification and individualized treatment. In the future, multidisciplinary collaboration and technological innovation are expected to improve the survival outcomes of this critically ill patient population.